

Dr Jane Osbourn from MedImmune to join Babraham Bioscience Technologies as a New Non-Executive Director

6th July 2015

Babraham Bioscience Technologies Ltd (BBT), which develops and manages the Babraham Research Campus, announced today that Dr Jane Osbourn, VP R&D and Site Leader of MedImmune in Cambridge, has joined the board as a non-executive director.

The Babraham Research Campus is a co-location of 60 life sciences business with the academic community of the Babraham Institute, providing facilities, capabilities and a unique ecosystem that supports the growth of companies in the life sciences sector. This ecosystem has been created and developed by Babraham Bioscience Technologies with strong support from the BBSRC and the Babraham Institute. The Babraham Research Campus is widely recognised as being at the epicentre of the dynamic Cambridge life-science cluster and a place where many successful ventures have grown from early stage to scaled businesses.

Jane Osbourn, PhD, is VP Research and Development for MedImmune's biosuperiors portfolio, as well as Site Leader of MedImmune's Cambridge, UK-based site. In 2010 Jane won the Institute of Directors East of England Business Woman of the Year Award in recognition of her contribution to the successful development and evolution of Cambridge Antibody Technology (CAT) and MedImmune in Cambridge. Jane is a member of the UK Medical Research Council Industry Grant award assessment panel and member of the board of the UK's BioIndustry Association (BIA). Jane was one of the early employees of CAT and has played a central role as the company has grown and become an integral part of AstraZeneca's innovation activities.

Dr Osbourn will be joining the BBT board alongside Dr Andy Richards CBE as Chairman, Derek Jones as Chief Executive and fellow Non-executive directors:- Professor Clive Page from Kings College London, David Parfrey (BBSRC – Executive Director Finance and Campus Operations), Keith Churchman and Richard Jonas.

Dr Osbourn said, "I am delighted to be joining the BBT board at such an exciting time for the Babraham Research Campus and the wider Cambridge life-science cluster. The Babraham Research Campus plays an important role in supporting life-sciences enterprises and I look forward to playing a part in ensuring this continues"

Dr Andy Richards CBE, Chairman of the BBT board added, "Jane has been a true champion of life-science in Cambridge. She brings a wealth of experience, not only from her time at CAT and MedImmune as a successful growing life-science company but she also brings a unique perspective from a major pharmaceutical company on how the interactions of global companies with our dynamic cluster can best be developed for the benefit of all. The BBT Board look forward to working with her in bringing these insights to the next stages of the development of Babraham".

About Babraham Bioscience Technologies

Babraham Bioscience Technologies Ltd Babraham Bioscience Technologies Ltd (BBT) is responsible for the management and commercial development of the Babraham Research Campus. The Babraham Research Campus is distinct in its co-location of 60 bioscience companies with the Babraham Institute, a world-renowned research organisation which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC). The Campus provides companies laboratory and office

space, networking and collaboration opportunities, together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster. Website: www.babraham.com

About MedImmune

MedImmune is the worldwide biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca's three global R&D centres. For more information, please visit: www.medimmune.com.